Beta Fulltext view is in preview — article structure may vary. Browse all articles
Contents
Open Access Journal of Pulmonary & Respiratory Sciences Editorial 5 min read

Post-Acute-COVID-19-Illness Neuropsychiatric Sequelae

Cheepsattayakorn A*
* Corresponding author
ISSN: 2642-1143  10.23880/oajprs-16000143  Received: June 18, 2021  Published: June 25, 2021
 — views
 30 references
PDF
Keywords
Acute-COVID-19 Neuropsychiatric Sequelae
Abstract

Direct viral invasion, neurodegeneration, microvascular thrombosis, neuroinflammation, and severe systemic inflammation can be the causes of post-acute-COVID-19- illness neuropathology [1-4], supported by brain parenchyma and vessel changes of possibly driven inflammation in neurons, supportive cells, and brain vasculature in COVID-19 autopsy series [5,6]

Introduction

Direct viral invasion, neurodegeneration, microvascular thrombosis, neuroinflammation, and severe systemic inflammation can be the causes of post-acute-COVID-19- illness neuropathology [1, 2, 3, 4], supported by brain parenchyma and vessel changes of possibly driven inflammation in neurons, supportive cells, and brain vasculature in COVID-19 autopsy series [5, 6]. A role in persistent brain effects of SARS- CoV-2 (COVID-19) may be played by an accumulation of memory T cells, a biomarker of immunosenescence in tissue injury and aging, accompanying with the decreased ability to respond to new antigens that are demonstrated in chronic low-level brain inflammation [7]. Cognitive-behavioral changes directly associated with the levels of immune activation [8]. Passive diffusion and axonal transport via the olfactory complex, viral invasion in the extracellular spaces of olfactory epithelium and dysfunctional lymphatic drainage from circumventricular organs [9, 10]. Elevated peripheral blood levels of neurofilament light chain, a biomarker of brain injury with a more sustained increase in severe infections has been identified in post-acute-COVID-19-illness phase. Post-traumatic-stress disorder (PTSD) or deconditioning may be mechanisms that are hypothesized in critically ill COVID-19 patients with post-acute-COVID-19-illness brain fog whereas dysautonomia may be the cause of post-acute- COVID-19-illness brain fog in previously mild-COVID-19 patients [11, 12, 13, 14, 15]. Approximately, 20 %-40 % of patients with previously critical-COVID-19 illness demonstrated long-term cognitive impairment [16]. Non-restorative sleep, depressive symptoms, diffuse myalgia, post-viral syndrome of chronic malaise late-onset headaches ascribed to high cytokine levels, and migraine-like headaches (frequently refractory to traditional analgesics have been reported in post-COVID-19 survivors. Around 38 % of post-acute-COVID-19-illness patients had ongoing headaches after 6 weeks [17, 18, 19, 20, 21, 22]. At up to 6 months follow-up, approximately, 10 % of post- acute-COVID-19-illness survivors may persist loss of smell and taste [23, 24, 25, 26]. Ischemic or hemorrhagic stroke hypoxic- anoxic brain damage, posterior reversible encephalopathy syndrome and acute disseminated myelitis [27, 28, 29, 30], may contribute to required-extensive-rehabilitation permanent or lingering neurological deficits.

Conclusion

In conclusion, further studies are urgently needed to identify the exact mechanisms and biomarkers of the neurological post-acute-COVID-19-illness sequelae.

References

  1. Heneka MT, Golenbock D, Latz E, Morga D, Brown R, et al. (2020) Immediate and long-term consequences of COVID-19 infections for development of neurological disease. Alzheimers Res Ther 12(1): 69.
  2. Muccioli L, Pensato U, Cani I, Guarino M, Cortelli P, et al. (2020) COVID-19-associated encephalopathy and cytokine-mediated neuroinflammation. Ann Neurol 88(4): 860-861.
  3. Pilotto A, Padovani A, Network EB (2020) Reply to the letter “COVID-19-associated encephalopathy and cytokine-mediated neuroinflammation”. Ann Neurol 88(4): 861-862.
  4. South K, McCulloch L, McColl BW, Elkind MS, Allan et al. (2020) Preceding infection and risk of stroke: an old concept revived by the COVID-19 pandemic. Int J Stroke 15(7): 722-732.
  5. Romero Sánchez CM, Díaz Maroto I, Fernández Díaz E, Sánchez Larsen Á, Layos Romero A, et al. (2020) Neurologic manifestations in hospitalized patients with COVID-19 : the ALBACOVID registry. Neurology 95(8): 1060-1070.
  6. Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, et al. (2020) Neuropathology of COVID-19: a spectrum of vascular and acute dissemeinated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol 140(1): 1-6.
  7. Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, et al. (2019) Immunosenescence and its hallmarks: how to oppose aging strategically ? A Review of potential options for therapeutic intervention. Front Immunol 10: 2247.
  8. Tolato B, Carvalho AF, Soczynska JK, Perini GI, McIntyre RS, et al. (2015) The involvement of TNF-α in cognitive dysfunction associated with major depressive disorder: an opportunity for domain specific treatments. Curr Neuropharmacol 13(5): 558-576.
  9. Morbini P, Benazzo M, Verga L, Pagella FG, Mojoliet F, et al. (2020) Ultrastructural evidence of direct viral damage to the olfactory complex in patients testing positive for SARS-CoV-2. JAMA Otolaryngol Head Neck Surg 146(10): 972-973.
  10. Perrin R, Riste L, Hann M, Walther A, Mukherjeeet A, et al. (2020) Into the looking glass : post-viral syndrome post COVID-19. Med Hypotheses 144: 110055.
  11. Ameres M, Brandstetter S, Toncheva AA, Kabesch M, Leppertet D, et al. (2020) Association of neuronal injury blood marker neurofilament light chain with mild-to- moderate COVID-19. J Neurol 267(12): 3476-3478.
  12. Kanberg N, Ashton NJ, Andersson LM, Yilmaz A, Lindh M, et al. (2020) Neurochemical evidence of astrocytic and neuronal injury commonlyfound in COVID-19. Neurology 95(12): 1754-1759.
  13. Kaseda ET, Levine AJ (2020) Post-traumatic stress disorder: a differential diagnostic consideration for COVID-19 survivors. Clin Neuropsychol 34(7-8): 1498- 1514.
  14. Novak P (2020) Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: a case report. eNeurologicalSci 21: 100276.
  15. Miglis MG, Goodman BP, Chémali KR, Stiles L (2020) Re: “Post-COVID-19 chronic symptoms” by Davido et al. Clin Microbiol Infect 27(3): 494.
  16. Sakusic A, Rabinstein AA (2018) Cognitive outcomes after critical illness. Curr Opin Crit Care 24(5): 410-414.
  17. Fauci A (2020) International AIDS conference.
  18. Nordvig AS, Rimmer KT, Willeye JZ, Thakurt KT, Boehme A, et al. (2020) Potential neurological manifestations of COVID-19. Neurol Clin Pract 11(2):10.
  19. Belvis R (2020) Headaches during COVID-19: my clinical case and review of literature. Headache 60: 1200-1203.
  20. Arca KN, Starling AJ (2020) Treatment-refractory headache in the setting of COVID-19 pneumonia: migraine or meningoencephalitis?: case report. SN Compr Clin Med 25: 1-4.
  21. Bolay H, Gül A, Baykan B (2020) COVID-19 is a real headache! Headache 60(7): 1415-1421.
  22. Rosich PP (2020) Headache and COVID-19: a short-term challenge with long-term insights. In Proc. AHSAM 2020 Virtual Annual Scientific Meeting (Infomedia,).
  23. Garrigues E, Janvier P, Kherabi Y, Bot AL, Hamonet A, et al. (2020) Post-discharge persistent symptoms and health- related quality of life after hospitalization for COVID-19. J Infect 81(6): 4-6.
  24. Chopra V, Flanders SA, O Malley M, Malani AN, Prescott HC, et al. (2021) Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern 174(4): 576- 578.
  25. Huang C, Huang L, Wang Y, Li X, Ren L, et al. (2021) 6-month consequences of COVID-19 in patients discharged from hospital : a cohort study. Lancet 397(10270): 220-232.
  26. Arnold DT, Hamilton FW, Milne A, Morley AJ, Vineret J, et al. (2020) Patient outcomes after hospitalization with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax 76(4): 399-401.
  27. Trejo Gabriel Galán JM (2020) Stroke as a complication and prognostic factor of COVID-19. Neurologia 35(5): 318-322.
  28. Parauda SC, Gao V, Gewirtz AN, Parikh NS, Merkleret AE, et al. (2020) Posterior reversible encephalopathy syndrome in patients with COVID-19. J Neurol Sci 416: 117019.
  29. Ellul MA, Benjamin L, Singh B, Lant S, Michaelet BD, et al. (2020) Neurological associations of COVID-19. Lancet Neurol 19(9): 767-783.
  30. Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, et al. (2020) The emerging spectrum of COVID-19 neurology : clinical, radiological and laboratory findings. Brain 143(10): 3104-3120.
More from this journal

Cite this article

BibTeX
APA
RIS
@article{cheepsattayakorn2021,
  title   = {Post-Acute-COVID-19-Illness Neuropsychiatric Sequelae},
  author  = {Cheepsattayakorn A},
  journal = {Open Access Journal of Pulmonary & Respiratory Sciences},
  year    = {2021},
  volume  = {6},
  number  = {1},
  doi     = {10.23880/oajprs-16000143}
}
Cheepsattayakorn A (2021). Post-Acute-COVID-19-Illness Neuropsychiatric Sequelae. Open Access Journal of Pulmonary & Respiratory Sciences, 6(1). https://doi.org/10.23880/oajprs-16000143
TY  - JOUR
TI  - Post-Acute-COVID-19-Illness Neuropsychiatric Sequelae
AU  - Cheepsattayakorn A
JO  - Open Access Journal of Pulmonary & Respiratory Sciences
PY  - 2021
VL  - 6
IS  - 1
DO  - 10.23880/oajprs-16000143
ER  -
BETA

Full Text Preview

This feature is under active development

We are still refining this page. Occasional formatting inconsistencies may appear in tables, figures, or text layout. Your patience is appreciated.